Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

298.90 -2.95 (-0.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,682,656
Open 299.24
Bid (Size) 294.00 (1)
Ask (Size) 298.70 (2)
Prev. Close 301.85
Today's Range 297.78 - 305.06
52wk Range 187.16 - 311.88
Shares Outstanding 147,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD). 
Via Benzinga

Performance

YTD
+22.43%
+22.43%
1 Month
+6.65%
+6.65%
3 Month
+53.53%
+53.53%
6 Month
+51.64%
+51.64%
1 Year
+33.49%
+33.49%

More News

Read More
CrowdStrike (CRWD) Stock Sinks on Weak Guidance
Via InvestorPlace
BIIB Stock Alert: What the Latest Alzheimer’s Drug Data Means for Biogen
Via InvestorPlace
26 Analysts Have This to Say About Biogen
Via Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
Via Benzinga
Biogen Stock Is Surging Today: What's Going On?
Via Benzinga
Alphabet To $135? Here Are 10 Other Price Target Changes For Wednesday
Via Benzinga
Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success
Via Investor's Business Daily
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
Via Benzinga
Market Currents: Why Pick Stocks?
Via Talk Markets
2 Stocks Near 52-Week Highs That Could Climb Higher
Via The Motley Fool
CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention
Via TheNewswire.com
Topics ETFs Economy Stocks
Exposures Interest Rates US Equities
CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention
Via News Direct
Topics ETFs Economy
Exposures Interest Rates
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Via Benzinga
CBOE's Weekly Market Recap: Nov.14-18 – Biogen's Alzheimer's Drug Captures Investors' Attention
Via Benzinga
Not All Offices Are Created Equal… You Can Profit From One Sector That’s Poised to See Demand Growth
Via Talk Markets
TEVA Stock Alert: What to Know About Teva Pharmaceuticals’ New CEO
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Stocks to Avoid Right Now
Via The Motley Fool
CONTINUED INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Continues to Investigate Biogen Inc.’s Directors and Officers for Breach of Fiduciary Duties – BIIB
From Scott+Scott Attorneys at Law LLP
Via Business Wire
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Via Investor's Business Daily
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.